{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096946","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.516965+00:00","generated_at":"2026-05-17T04:41:10.537078+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Theriva presents preclinical data for VCN-12 oncolytic adenovirus at ESGCT congress","bullets":["VCN-12, derived from VCN-01, armed with transgenes to improve tumor lysis, stroma degradation, and antitumor immune response.","Presentation at ESGCT 2025 in Seville, Spain on October 8, 2025, by co-founder Dr. Ramón Alemany.","Preclinical study published in Human Gene Therapy shows intracranial VCN-01 administration feasible for brain tumor treatment.","Study concludes findings provide strong rationale for VCN-01 development as therapy for brain tumors.","No financial guidance or material changes to business operations announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096946","json":"https://secwatch.observer/filing/0001104659-25-096946.json","markdown":"https://secwatch.observer/filing/0001104659-25-096946.md","text":"https://secwatch.observer/filing/0001104659-25-096946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/0001104659-25-096946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/tm2528055d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:41:10.537078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}